Among 173 RA patients with overweight or obesity who were prescribed GLP-1 agonists and actually took them, 32% showed improvement in RA disease activity after 1 year, compared with 17% of 42 patients who were also prescribed the drugs but never started them, according to Veena Ranganath, MD, MS, of the University of California Los Angeles (UCLA), and colleagues
Call our office at (949) 888-0404 to discuss with Dr
GHK-Cu has been shown in preclinical studies to modulate over 4,000 human genes related to tissue remodeling, making the Glow blend particularly relevant for researchers studying skin biology, wound healing, and aging
Its important to manage expectations, as the body takes time to acclimate to the medication and begin experiencing the full benefits